lipoplatin

liposomal cisplatin formulation formed from cisplatin and liposomes composed of dipalmitoyl phosphatidyl glycerol (DPPG), soy phosphatidyl choline (SPC-3), cholesterol and methoxy-polyethylene glycol-distearoyl phosphatidylethanolamine (mPEG2000-DSPE); has no nephrotoxicity and lacks the serious side effects of cisplatin

Networked: 32 relevant articles (5 outcomes, 14 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Boulikas, Teni: 7 articles (09/2010 - 07/2004)
2.	Krueger, Thorsten: 3 articles (01/2018 - 04/2015)
3.	Perentes, Jean Y: 3 articles (01/2018 - 04/2015)
4.	Ris, Hans-Beat: 3 articles (01/2018 - 04/2015)
5.	Fortin, David: 3 articles (06/2015 - 04/2010)
6.	Paquette, Benoit: 3 articles (06/2015 - 04/2010)
7.	Sanche, Léon: 3 articles (06/2015 - 04/2010)
8.	Froudarakis, Marios E: 3 articles (04/2011 - 01/2007)
9.	Cavin, Sabrina: 2 articles (01/2018 - 10/2017)
10.	Gonzalez, Michel: 2 articles (10/2017 - 04/2015)

Related Diseases

1.	Neoplasms (Cancer) 07/01/2005 - "Systemic Lipoplatin infusion results in preferential tumor uptake in human studies." 08/08/2016 - "To improve the effectiveness of Lipoplatin, enhancing the cellular sensitivity of lung tumor and MPM cells is critical. " 11/01/2014 - "We evaluated in vivo the lipoplatin anticancer activity using tumor xenografts. " 12/01/2013 - "The ability of R-ME-180 cells to form spheroids in vitro and tumors in nude mice was also remarkably decreased by lipoplatin. " 01/01/2013 - "Further investigations are needed to use this new targeted lipoplatin in treatment of malignancies. "
2.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/01/2009 - "Lipoplatin monotherapy: A phase II trial of second-line treatment of metastatic non-small-cell lung cancer." 05/01/2010 - "Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer." 11/01/2008 - "The aims of this preclinical study were to compare lipoplatin and cisplatin cytotoxicity in vitro in established cell lines derived from non-small cell lung cancer, renal cell carcinoma, and in normal hematopoietic cell precursors, and to identify biological markers associated with sensitivity and resistance. "
3.	Neuroblastoma 09/01/2022 - "For the treatment of neuroblastoma, the use of lipoplatin seems to be beneficial in reducing side effects of cisplatin. " 09/01/2022 - "Comparison of Cytotoxic and Ototoxic Effects of Lipoplatin and Cisplatin in Neuroblastoma In Vivo Tumor Model." 09/01/2022 - "This study aimed to compare the cytotoxic, cytostatic, and ototoxic effects of lipoplatin compared to cisplatin application in the subcutaneous xenograft nude mouse neuroblastoma tumor model. "
4.	Squamous Cell Carcinoma of Head and Neck 08/01/2009 - "Lipoplatin has finished successfully one Phase III non-inferiority clinical study as first-line against NSCLC in its combination with paclitaxel showing statistically significant reduction in nephrotoxicity; two more Phase III studies are in progress, one in NSCLC with gemcitabine also showing noninferiority with reduced toxicity and another in squamous cell carcinoma of the head and neck with 5-fluorouracil. "
5.	Adenocarcinoma 03/01/2006 - "Clonogenic data revealed a significant (P<0.05) 2-fold resistance to lipoplatin of HCT116 human colorectal adenocarcinoma cells lacking MLH1, one of five proteins crucial to MMR function, as compared to MLH1-expressing HCT116 cells. " 07/01/2005 - "We explored the hypothesis that intravenous infusion of Lipoplatin results in tumor targeting in four independent patient cases (one with hepatocellular adenocarcinoma, two with gastric cancer and one with colon cancer) who underwent Lipoplatin infusion followed by a prescheduled surgery approximately 20 h later. " 11/01/2006 - "Human colorectal adenocarcinoma sublines either deficient (HCT116+ch2) or proficient (HCT116+ch3) in the function of MLH1, one of five proteins crucial to DNA mismatch repair (MMR), were used to investigate whether the Akt-specific inhibitor LY294005 could not only increase the efficacy of platinum drugs in HCT116 cells in general but also increase the efficacy of the cisplatinum compounds Cisplatin and Lipoplatin specifically in MLH1-deficient, Cisplatin- and Lipoplatin-resistant HCT116 cells. "

Related Drugs and Biologics

1.	Cisplatin (Platino)
2.	Gemcitabine
3.	Fluorouracil (Carac)
4.	Platinum
5.	Paclitaxel (Taxol)
6.	Proteins (Proteins, Gene)
7.	1L-6-hydroxymethyl-chiro-inositol 2(R)-2-O-methyl-3-O-octadecylcarbonate
8.	Carboplatin (JM8)
9.	Oxaliplatin (Eloxatin)
10.	Cytostatic Agents

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Radiotherapy
3.	Therapeutics
4.	Photochemotherapy (Photodynamic Therapy)
5.	Intravenous Injections